BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry

Boulder, Colorado, January 22, 2015 – BiOptix is pleased to announce the appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry. Scott joins the company after previous scientific leadership positions at Takeda Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course of his nearly 20 year career in therapeutics discovery and development.

“Scott is a nationally recognized thought leader in the biosensor field and particularly in the biophysical characterization of molecular interactions,” commented Rick Whitcomb, President and CEO of BiOptix. “It is a testament to BiOptix’ future prospects to be able to attract someone of Scott’s caliber. With the addition of Scott to our leadership team, we are poised to add significantly more value to our SPR instrument platform, and this in turn will contribute to making our customers in drug discovery more successful,” continued Whitcomb.

“I am excited to join BiOptix, a company on the forefront of biosensor technology. I look forward to working with our scientific and engineering teams to enhance the biophysical characterization of molecular interactions – which will aid in improving the drug discovery paradigm” said Dr. Klakamp.